Compare Danaher Corporation (DHR) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Danaher Corporation trades at $201.01 (market cap $140.88B), while iShares 20 Plus Year Treasury Bond ETF trades at $84. The key difference: Danaher Corporation pays a 0.8% dividend while iShares 20 Plus Year Treasury Bond ETF pays none, and Danaher Corporation is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| DHR | TLT | |
|---|---|---|
Market Cap | $140.88B | — |
Sector | Health | — |
52-Week High | $242.05 | $92.06 |
52-Week Low | $161.91 | $83.02 |
Enterprise Value | $153.66B | — |
Dividend Yield | 0.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $199.05, down 0.55% today, with a bullish technical outlook supported by moving averages and a consensus price target of $211.33. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.06 exceeding expectations. Revenue for 2025 was $24.57 billion, with a net income margin of 14.89%, though margins have declined from 2022 levels. Recent news includes the acquisition of Masimo and strong biotechnology segment performance.
The stock presents a favorable risk-reward profile with analyst support (69% buy ratings) and solid cash flow generation, but faces risks from margin compression and a high P/E ratio of 38.58. Upside is driven by earnings beats and strategic acquisitions, while headwinds include competitive pressures and macroeconomic uncertainty. The current price near $199 offers modest upside to the consensus target, with key resistance at $200.
TLT trades at $83.97, down 0.59% with a bearish technical signal from moving averages. The ETF faces mixed sentiment as fixed income sees renewed interest amid economic uncertainty. Recent dividend payments of $0.32-$0.34 highlight income generation, while technical indicators show oversold conditions with RSI at 27.67 suggesting potential rebound opportunity.
Long-term Treasury bonds offer attractive yields but face interest rate sensitivity. The Fed's hawkish stance presents near-term headwinds, though TLT's 4-5x higher starting yields than pre-crisis levels provide income appeal. Investors must weigh duration risk against potential Fed policy shifts and inflation trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
